Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Standard Biotools (LAB) EBT Margin (2016 - 2025)

Standard Biotools (LAB) has disclosed EBT Margin for 16 consecutive years, with 195.42% as the latest value for Q4 2025.

  • Quarterly EBT Margin rose 20612.0% to 195.42% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 29.14% through Dec 2025, up 4213.0% year-over-year, with the annual reading at 33.01% for FY2025, 3967.0% up from the prior year.
  • EBT Margin for Q4 2025 was 195.42% at Standard Biotools, up from 168.27% in the prior quarter.
  • The five-year high for EBT Margin was 195.42% in Q4 2025, with the low at 346.98% in Q2 2022.
  • Average EBT Margin over 5 years is 83.09%, with a median of 70.33% recorded in 2024.
  • The sharpest move saw EBT Margin surged 47493bps in 2021, then plummeted -29004bps in 2022.
  • Over 5 years, EBT Margin stood at 53.55% in 2021, then plummeted by -44bps to 76.88% in 2022, then skyrocketed by 163bps to 48.53% in 2023, then tumbled by -122bps to 10.7% in 2024, then skyrocketed by 1926bps to 195.42% in 2025.
  • According to Business Quant data, EBT Margin over the past three periods came in at 195.42%, 168.27%, and 84.01% for Q4 2025, Q3 2025, and Q2 2025 respectively.